Infectious side effects of cancer treatment in children. Clinical and genetic aspects
PhD ceremony: Ms. E.M. te Poele, 14.30 uur, Academiegebouw, Broerstraat 5, Groningen
Dissertation: Infectious side effects of cancer treatment in children. Clinical and genetic aspects
Promotor(s): prof. E.S.J.M de Bont, prof. W.A. Kamps
Faculty: Medical Sciences
Chemotherapy has significantly improved the survival of children with cancer. One of the side effects of chemotherapy is the inhibited production of white blood cells. This effect predisposes for infections and infectious complications. Therefore, fever during neutropenia (lack of a specific type of white blood cells) is treated with intravenous antibiotics. The first part of this thesis deals with clinical issues. We examined the possibilities for a better risk assessment of fever during neutropenia to prevent overtreatment of patients with a low risk for bacterial infections. This cost-efficient approach may contribute to a better quality of life.
Subsequently, we studied the number of infectious deaths during the ALL-9 protocol (treatment for acute lymphoblastic leukemia (ALL) in children). We found an increase in the number of infectious deaths compared to previous protocols. This is most probably caused by repeated, prolonged treatment with the drug Dexamethasone in ALL-9. Furthermore, the use of Pegfilgrastim was evaluated. This medicine may be administered to reduce chemotherapy induced neutropenia. Pegfilgrastim is only registered for use in adults, but also seems to be safe for children. Lastly, we studied the mortality of non-elective ICU admissions in children with cancer. One of the conclusions of this study is that the survival of these children increased significantly. The second part of this thesis concerns several studies of genetic variants and the risk of developing ALL and (fever during) neutropenia. It was concluded that particular genetic variants that are associated with atopy have an inverse association with ALL.
Last modified: | 13 March 2020 01.02 a.m. |
More news
-
27 August 2024
UMCG gaat onderzoeksfaciliteiten beschikbaar stellen voor geneesmiddelenontwikkeling
Om de beschikbaarheid en effectiviteit van geneesmiddelen in Nederland te verbeteren gaat het UMCG het bedrijf G² Solutions opzetten. Dit bedrijf moet ervoor gaan zorgen dat belangrijke technologische ontwikkelingen op het gebied van DNA sequencing...
-
17 July 2024
Veni-grants for ten researchers
The Dutch Research Council (NWO) has awarded a Veni grant of up to €320,000 each to ten researchers of the University of Groningen and the UMCG. The Veni grants are designed for outstanding researchers who have recently gained a PhD.
-
16 July 2024
Medicine still subjects to male bias
Aranka Ballering studied the course of illness in people with common symptoms. One of the most striking findings to emerge from her research was that on average, women have a different – and less extensive – course of illness than men.